Cancer Research Horizons
VC Fund
London, United Kingdom
Cancer Research Horizons is a VC fund in London focused on Biotechnology and Health Care. Cancer Research Horizons develops and commercialises exciting new discoveries in cancer research. They’re the meeting point between academia and industry. Their deep understanding of both perspectives enables them to translate promising research into commercial propositions for the greatest patient benefit and maximum financial return. CRT isuniquely placed to capitalise on the research and connections of theirr parent organisation Cancer Research UK, the world’s largest charitable funder of cancer research and the strong links they’ve established with leading clinical and academic institutions, pharmaceutical companies and biotechs worldwide. CRT has 30 years’ specialist experience in the commercialisation of cancer research and a proven track record of successful innovation. CRT personnel are experienced, dedicated and highly motivated with an average length of service of nearly 6 years. The workforce is split between drug discovery and commercialisation for a comprehensive approach to getting breakthrough therapeutics to patients.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 6%
Last updated:
For AI agents: llms.txt
Industries Cancer Research Horizons invests in
Stages Cancer Research Horizons invests in
Countries Cancer Research Horizons invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Deborah Harland
|
|||
Raj Mehta
|
|||
Raj Mehta
|
|||
Investment Focus
Industry
- Biotechnology 8 (47%)
- Health Care 7 (41%)
- Medical 5 (29%)
- Therapeutics 5 (29%)
- Medical Device 4 (24%)
Stage
- Seed 8 (47%)
- Series A 3 (18%)
- Pre-Seed 2 (12%)
- Funding Round 1 (6%)
Country
- United Kingdom 9 (53%)
- United States 2 (12%)
- The Netherlands 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Deborah Harland
Non Executive Director
|
Non Executive Director | Total investments: 11 | Find email | |
|
Raj Mehta
Team Member
|
Team Member | Total investments: 0 | Find email | |
|
Raj Mehta
Team Member
|
Team Member | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Laigo Bio
|
Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and inflammatory disorders. | $6.4M / Seed / Mar 23, 2026 | |
Infinitopes
|
Infinitopes is a cancer research organization whose mission is to strengthen the immune system so that it can stop metastases and save lives. The company's platform creates healthcare systems and therapy designs to integrate high-efficiency vector delivery systems with optimal tumor target identification technologies in early-stage clinicaltrials, allowing patients to prevent cancer and tumors from taking their lives | $15.4M / Seed / Jan 21, 2026 | |
|
Infinitopes
|
Infinitopes is a cancer research organization whose mission is to strengthen the immune system so that it can stop metastases and save lives. The company's platform creates healthcare systems and therapy designs to integrate high-efficiency vector delivery systems with optimal tumor target identification technologies in early-stage clinicaltrials, allowing patients to prevent cancer and tumors from taking their lives | $15.4M / Seed / Jan 21, 2026 | |
Verinnogen
|
Verinnogen is a biotechnology company that works in pre-clinical cancer research and medical devices. | Pre-Seed / Dec 22, 2025 | |
|
Laigo Bio
|
Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and inflammatory disorders. | $13.4M / Seed / Dec 03, 2025 | |
Trogenix
|
Trogenix operates as a therapeutics company, that treats aggressive cancers. | $94.4M / Series A / Oct 06, 2025 | |
AiM Medical Robotics
|
AiM Medical Robotics developing a robotic system for use in neurosurgical procedures. The system is unique in that it is MRI compatible, allowing patients to be treated while in the MRI scanner. This gives physicians the ability to capture real-time imaging feedback to improve outcomes. Its system will help treat patients with Parkinson's,Epilepsy, Tremors, and brain cancer. | $8.1M / Series A / Sep 30, 2025 | |
52 North Health
|
52 North Health aims to improve healthcare with a medical device that uses artificial intelligence (AI) to determine the risk of neutropenic sepsis for patients undergoing chemotherapy. | $6M / Dec 03, 2024 | |
Myricx Bio
|
Myricx Pharma is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across other diseases. | $115.3M / Series A / Jul 08, 2024 | |
|
Infinitopes
|
Infinitopes is a cancer research organization whose mission is to strengthen the immune system so that it can stop metastases and save lives. The company's platform creates healthcare systems and therapy designs to integrate high-efficiency vector delivery systems with optimal tumor target identification technologies in early-stage clinicaltrials, allowing patients to prevent cancer and tumors from taking their lives | $16M / Seed / Apr 30, 2024 | |
| See all 17 investments → | |||
Co-Investors
IQ Capital
4 deals together
Macmillan Cancer Support
3 deals together
Manta Ray Ventures
3 deals together
Meltwind Advisory
3 deals together
Octopus Ventures
3 deals together
4BIO Capital
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Cancer Research Horizons invest in?
Cancer Research Horizons invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 17 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Cancer Research Horizons?
Public channels for Cancer Research Horizons include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Cancer Research Horizons?
The team at Cancer Research Horizons includes Deborah Harland (Non Executive Director), Raj Mehta (Team Member) and Raj Mehta (Team Member). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
